Bicycle Therapeutics PLC
NASDAQ:BCYC

Watchlist Manager
Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC
NASDAQ:BCYC
Watchlist
Price: 14.73 USD 0.34%
Market Cap: 1B USD
Have any thoughts about
Bicycle Therapeutics PLC?
Write Note

Bicycle Therapeutics PLC
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bicycle Therapeutics PLC
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Bicycle Therapeutics PLC
NASDAQ:BCYC
EPS (Diluted)
-$2
CAGR 3-Years
3%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
EPS (Diluted)
-$1
CAGR 3-Years
-136%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
EPS (Diluted)
-ÂŁ1
CAGR 3-Years
-69%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
EPS (Diluted)
-$1
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
EPS (Diluted)
-ÂŁ1
CAGR 3-Years
14%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
EPS (Diluted)
ÂŁ0
CAGR 3-Years
-45%
CAGR 5-Years
0%
CAGR 10-Years
-13%
No Stocks Found

Bicycle Therapeutics PLC
Glance View

Market Cap
1B USD
Industry
Biotechnology

Bicycle Therapeutics PLC, a pioneering force in biotechnology, was founded on a unique vision to transform medicine using a novel class of therapeutics known as Bicycles®. These are synthetic short peptides that combine the pharmacological capabilities of biologics with the manufacturing and distribution advantages of small molecules. The company's scientific ingenuity, originating from Cambridge, UK, has enabled it to engineer and develop a pipeline of drugs targeting areas with significant unmet medical needs, primarily in oncology and other severe diseases. Bicycle leverages its distinctive platform technology to design therapeutic candidates that offer high specificity and affinity, focusing on targets that have traditionally been challenging for conventional biologics and small molecules. Monetizing this innovative biotechnology hinges on Bicycle's strategic partnerships and collaborations with major pharmaceutical firms. These alliances allow the company to amplify its reach while sharing the risks and costs associated with drug development. By licensing their Bicycle® technology and therapeutic candidates to larger entities, Bicycle benefits from milestone payments and royalty streams, creating a sustainable revenue model. The company's revenue stream is thus a blend of upfront payments for access to their platform technology and the potential downstream success of these partners in developing and commercializing new therapeutic agents. Their unique approach and strong collaboration network position Bicycle Therapeutics at the forefront of next-generation drug discovery, striving to reshape treatment paradigms across multiple therapeutic areas.

BCYC Intrinsic Value
9.02 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Bicycle Therapeutics PLC's EPS (Diluted)?
EPS (Diluted)
-2.4 USD

Based on the financial report for Sep 30, 2024, Bicycle Therapeutics PLC's EPS (Diluted) amounts to -2.4 USD.

What is Bicycle Therapeutics PLC's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-5%

Over the last year, the EPS (Diluted) growth was 41%. The average annual EPS (Diluted) growth rates for Bicycle Therapeutics PLC have been 3% over the past three years , -5% over the past five years .

Back to Top